Skip to main content
RYTM
NASDAQ Life Sciences

Q3 Revenue Up 4% but RYTHM Withholds Q4 Outlook as Federal THC Ban Looms

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$85.7
Mkt Cap
$5.952B
52W Low
$74.5
52W High
$122.2
52W Position info
15% above low
Off High info
30% below high
Rel. Volume info
9.4× avg
Market data snapshot near publication time

RYTM sits 15% above its 52-week low of $74.5 on elevated volume (9.4× avg).

Summary

RYTHM posted Q3 revenue of $23.9 million, up 4% from $23.0 million in Q2, with operating income of $1.0 million and adjusted EBITDA of $5.9 million versus $6.4 million last quarter, and a loss per share of 7 cents. Cash rose to $48.2 million on $6.3 million of operating cash flow, and hemp-derived product revenue grew 15% sequentially to $6.4 million. The problem is the outlook: management refused to guide Q4 because federal changes taking effect December 11, 2026 would prohibit selling its current hemp-derived THC products in their existing form, with Illinois restrictions starting even earlier on November 12. That ban threatens the exact beverage and retail channels driving the growth story, and the company still carries $72 million of related-party debt due currently against $42 million of equity. Green Thumb will consolidate RYTHM's results starting October 10, 2026, after the ownership-limit removal, which changes how the stock trades relative to its parent. Watch December 11 for whether Congress amends the federal hemp prohibition before it takes effect.

At the time of this announcement, RYTM was trading at $85.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

RYTM - Latest Insights

RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $104.94 info
Change: -$4.81 (-4%) info
Market Cap: $7.276B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $104.94 info
Change: +$9.73 (+10%) info
Market Cap: $7.276B info
RYTM
Nov 04, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $88.42
Real-time Price: $104.94 info
Change: +$16.52 (+19%) info
Market Cap: $7.276B info
RYTM
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $86.44
Real-time Price: $104.94 info
Change: +$18.50 (+21%) info
Market Cap: $7.276B info
RYTM
Nov 03, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $89.50
Real-time Price: $104.94 info
Change: +$15.44 (+17%) info
Market Cap: $7.276B info